DOI:
10.1039/C5RA12304F
(Paper)
RSC Adv., 2015,
5, 60024-60032
Green synthesis of reduced graphene oxide by a GRAS strain Bacillus subtilis 168 with high biocompatibility to zebrafish embryos
Received
25th June 2015
, Accepted 29th June 2015
First published on 29th June 2015
Abstract
Low toxic and highly biocompatible graphene-based nanomaterials are in high demand within the biomedical fields. In this study, a highly biocompatible bacterially reduced graphene oxide (BRGO) was prepared by a “Generally Recognized As Safe” (GRAS) strain Bacillus subtilis 168 mediated with Vitamin K3 (VK3). The hypothesis of VK3 mediating electron transfer between succinate:quinine oxidoreductase, from B. subtilis 168, and graphene oxide (GO) was proposed. BRGO was characterized by Raman spectroscopy, XPS and XRD and showed excellent properties. Furthermore, BRGO illustrates greater biocompatibility, with less toxicity, than GO and chemically reduced graphene oxide (CRGO) by zebrafish toxicity assessment, which demonstrates its great potential in various biomedical applications.
Introduction
Graphene, consisting of a single-layer sp2-hybridized carbon atom network, is a rapidly rising star in the field of material science.1 It has attracted a significant amount of attention in recent decades, due to its exceptionally high crystal and electronic qualities, such as high surface-to-volume ratio,2 high electrical3 and thermal conductivity,4 high mechanical strength,5 etc. Therefore, graphene and its derivatives are being studied in almost all fields of science, medicine and engineering.6 The application of graphene-based nanomaterials has been inclusively illustrated in medicine,7 electronics,8 energy storage,9,10 electrochemical sensors6 and so on. In particular, much attention has been paid to biomedical applications of graphene-based nanomaterials ranging from tissue engineering,11 bioimaging,12,13 and drug delivery14,15 to biosensors,16 over the past 5 years.
Differing from other applications, low toxicity and high biocompatibility are essential characteristics for biomedical applications, especially in vivo.17 As the most promising method for large scale production of graphene, the process of chemical synthesizing graphene first oxidized the graphite to graphene oxide (GO)18–20 and then reduced the GO to graphene, using strong chemical reducing agents in organic solvents,2,21 such as hydrazine and sodium borohydride. Unfortunately, these strong chemical reducing agents and solvents usually are highly corrosive and toxic. For example, acute exposure to hydrazine can damage the human liver, kidneys, and central nervous system.22 Therefore, the development of more biocompatible and eco-friendly approaches to GO reduction has been attempted. Several biological molecules have been used as reducing agents, such as sodium citrate,23 vitamin C,24 reducing sugars25 and microorganisms.26
Among all these greener processes, bacterial reduction of GO has drawn a lot of attention. Since Salas first reported the production of graphene by reduction of GO via Shewanella respiration,26 many other microbial species, including Escherichia fergusoni,27 Extremophiles bacteria,28 Pseudomonas aeruginosa,29 Gluconacetobacter xylinus,30 Bacillus marisflavi31 and Shewanella oneidensis MR-1,32 have successfully demonstrated their ability to reduce GO to graphene by themselves or with redox mediators. Recently two groups, independently, reported methods for the preparation of nitrogen (N) and sulfur (S)-doped graphenes, through bacterial treatment of GO.33,34 All these bacterial reducing processes of GO were under mild and safe conditions and some bacterially reduced graphene oxide (BRGO) products showed good biocompatibility and potential in biomedical applications.
Bacillus subtilis is an important variety of industrial microorganism, which has a long application history in fermenting food35 and is used mainly for the production of all kinds of industrial enzymes. B. subtilis has been used as a probiotic supplement and is known to be a “Generally recognized as safe” (GRAS) strain (Title 21 of the Code of Federal Regulations [21 CFR] and FDA Office of Premarket Approval list of microorganisms). Therefore in the present study, we report a method to reduce GO utilizing B. subtilis 168 as the reducing agent, in the presence of Vitamin K3 (VK3) acting as the redox mediator. Compared with previously reported microorganisms for GO reduction, B. subtilis is safer and can decrease the risks of introduction of toxic metabolites in biomedical applications. The composition and structure characteristics of BRGO and GO were determined by Raman spectroscopy, Scanning electron microscopy (SEM), Transmission electron microscope (TEM), X-ray photoelectron spectroscopy (XPS) and X-ray diffraction (XRD). The hypothesis of VK3 mediating electron transfer between succinate:quinine oxidoreductase (SQR) from B. subtilis 168 and GO is proposed. Furthermore, the toxicity and biocompatibility of BRGO were evaluated by the in vivo toxicity assessment including hatching rate, viability, heart rate and body length using a zebrafish model. BRGO showed lower toxicity and higher biocompatibility when compared to GO and chemically reduced graphene oxide (CRGO), which illustrates BRGO's prospects in biomedical applications such as drug delivery, tissue engineering and so on.
Materials and methods
Reagents, chemicals and strains
GO was purchased from Nanjing XFNANO Materials Tech Co., Ltd. VK3 was purchased from Sigma-Aldrich (USA). 2-n-Heptyl-4-hydroxyquinoline-N-oxide (HQNO) was purchased from Cayman Chemical Company (USA). All other chemicals used were reagent grade or better. All aqueous solutions were dissolved with ultrapure water, which was prepared by an EPED-superpure water system (EPED-20TS, Shanghai Precision Instrument Co., LTD). All of the M9 medium, LB medium and GO were dissolved with ultrapure water, but VK3 was dissolved with ethanol absolute. B. subtilis 168 (ATCC23857) was purchased from ATCC (USA).
Bacterial reduction of GO
B. subtilis 168 was grown in LB medium, at 37 °C for 12 h, with shaking at 200 rpm. The bacterium was harvested by centrifugation (10
000g, 5 min) and washed thrice in sterile M9 medium (containing Na2HPO4·7H2O, 12.8 g L−1; K2HPO4, 3 g L−1; NaCl, 0.5 g L−1; NH4Cl, 1 g L−1; MgSO4, 0.24 g L−1; CaCl2, 0.011 g L−1; glucose, 4 g L−1, pH 7.0). The resulting cell pellets were suspended in M9 medium. Final concentration of the cell resuspension solution was approximately 0.5 × 109 cells per mL. The experimental systems were carried out in 25 mL serum bottles containing 10 mL of cell resuspension solution, 10 μg VK3 and 5 mg GO. Samples were periodically taken and analyzed spectrometrically, as described below. Control experiments, using solely B. subtilis 168 and solely VK3, were also performed. The reactions operated at 25 ± 2 °C.
Succinate:quinine oxidoreductase (SQR) inhibition assay
In order to understand the mechanism of the VK3 mediated B. subtilis reduction of GO, an SQR inhibition assay was carried out. The assay was performed similarly to the bacterial reduction assay of GO, but varied the concentration of SQR inhibitor present in the system. In each system, there is 10 mL of cell resuspension (approximately 0.2 × 109 cells per mL), 10 μg VK3, 5 mg GO and various amounts of HQNO, which is 0 μmol L−1, 10 μmol L−1, 50 μmol L−1 and 100 μmol L−1, respectively. The corrected OD600 absorbance values of each system were analyzed over time.
Analytical methods
GO reduction was monitored by a Multimode Microplate Reader (Molecular Devices SpectraMax Paradigm, USA), which detected the increase of OD600 after correcting for bacterial cells. The Raman spectra of pure carbon-based materials were measured using a LabRam HR Evolution Raman Spectrometer (Jobin-Yvon Horiba Scientific, France) with a Confocal Microscope at room temperature. SEM images were obtained by a Quanta200 field emission transmission electron microscope (Philips, Japan). TEM images were taken with a JEM-200CX microscope (JEOL, Japan). The X-ray diffractometer (Smartlab, Japan), equipped with Cu Kα radiation (λ = 0.1541 nm) over the 2θ range of 5–90°, was used to characterize the X-ray diffraction (XRD) of the samples. X-ray photoelectron spectra (XPS) were performed on a PHI 5000 VersaProbe Spectrometer (UlVAC-PHI, Japan).
Zebrafish housing and embryo collection
Wild-type zebrafish (Danio rerio; Tubingen line) were obtained from the Model Animal Research Center of Nanjing University. As previously described,36 adult zebrafish, less than 1 year-old, were maintained at 28.5 °C and a pH of 7 ± 0.2 using a 14
:
10 h light–dark photoperiod. They were fed with live brine shrimp once daily and dry shrimp flakes twice a day.37 Embryos were produced by pair-wise mating and raised at 28.5 °C in embryo medium (0.2 g L−1 of Instant Ocean® Salt in distilled water with 0.01% methylene blue). The zebrafish studies were approved by the Institutional Animal Care and Use Committee (IACUC) at Nanjing Tech University. All zebrafish studies were carried out strict accordance with the recommendations in the “Guide for the Care and Use of Laboratory Animals” of the Jiangsu Institutes of Health.
Embryo toxicity test
Healthy embryos at 2 hours post fertilization (hpf) were selected and arrayed in a 48-well plate with 10 embryos per well. Embryos were then exposed to GO, CRGO, and BRGO each at 4 concentrations (0, 20, 50, 100, and 200 mg L−1) dispersed in embryo medium. Three replicates were used for each concentration. All 48-well plates were kept at 28.5 °C with a 14
:
10 light–dark cycle.
The development of zebrafish embryos and larvae was observed under a dissecting microscope (Nikon, SMZ745T). The toxicological endpoint was at 72 hpf, including hatching rate, viability, heart rate, length of larvae and malformations. For mortality, death was defined as absence of heartbeat for larvae. The heart beat was observed clearly and recorded by an experimenter with a stopwatch. Larval length was measured using the microscope ruler.
Statistics
All biological experiments were repeated at least three times. Values were given as mean ± S.E.M. Data were analyzed using GraphPad Prism 5.0 software. Statistical significance was assessed by one-way ANOVA, and P values less than 0.05 were considered significant.
Results and discussion
Bacterial reduction of GO
Four formulations ((I) blank control (M9 medium), (II) redox mediator (VK3), (III) B. subtilis 168 (B) and (IV) B. subtilis 168 with redox mediator (B + VK3)) were added to the suspension of GO (0.5 mg mL−1) and incubated in the incubator at 25 °C for 24 hours under anaerobic conditions. As shown in Fig. 1, at start point, all 4 groups were yellowish brown, which was the color of the GO solution. In as fast as 0.5 hour, the reduction of GO was observed by the change of the solution color from yellowish brown to black precipitate in bottle (IV), which contained both B. subtilis 168 as reducing agent and VK3 as redox mediator. This color change can be attributed to the distinct structural and physicochemical properties between GO and BRGO. GO has numerous hydrophilic functional groups, which gives it good solubility, while BRGO has mostly hydrophobic groups which, in solution cause the formation of a black precipitate. In the control groups, there is no evident color change in either the only-bacterially-treated or the only-redox-mediator-treated GO in M9 solution.
 |
| | Fig. 1 Time-course digital photographs of GO reduction with different reaction conditions: (I) blank control, (II) redox mediator (VK3), (III) B. subtilis 168, (IV) B. subtilis 168 with redox mediator (VK3). | |
In order to quantitatively analyze the reduction of GO, the corrected OD600 absorbance values of the samples were monitored.38 As shown in Fig. 2a, there was an obvious difference between GO treated with both B. subtilis 168 and VK3 (B + VK3) and the two controls (B and VK3) in the first 0.5 hour of reaction. For the controls, the corrected OD600 was 0.263(B) and 0.195(VK3), respectively, while the corrected OD600 of reduced GO (B + VK3) was 0.898. Afterwards, there was almost no increase of the corrected OD600 for the controls, while that for BRGO (B + VK3) rose rapidly. Up to 10 hours, the corrected OD600 value (B + VK3) reached 2.09 and continued stable then, which implied that the reaction basically was over. The huge differences in the corrected OD600 values between BRGO (B + VK3) and controls (B and VK3) indicate that the synergistic effect of the redox mediator VK3 and B. subtilis 168 is critical for GO reduction.
 |
| | Fig. 2 Corrected OD600 values change over time: (a) corrected OD600 values change over time on GO reduction with different reaction conditions (GO + VK3 was shown in black squares, GO + B was shown in red dots, GO + B + VK3 was shown in blue triangles) (b) corrected OD600 values change of SQR inhibition assay (the concentration of HQNO, which was 0 μmol L−1, 10 μmol L−1, 50 μmol L−1 and 100 μmol L−1, was shown in black squares, red dots, blue equilateral triangles and green inverted triangles, respectively). | |
Reaction mechanism analysis
So far, many bacteria have been reported to reduce GO to graphene by electron transfer directly or with exogenous redox mediators.27–33 For example, Pseudomonas aeruginosa29 and sulfate-reducing bacteria33 can reduce GO to graphene by direct electron transfer. Shewanella has been reported to reduce GO to graphene by direct electron transfer through cytochromes MtrA, MtrB, and MtrC/OmcA.26 Nevertheless, quinone mediators can also promote shewanella's GO reduction rate.32
In our study, B. subtilis could only reduce GO to graphene with the presence of redox mediator VK3. VK3 (menadione), also known as “menaphthone” belongs to the quinone superfamily, which has both a reduced hydroquinone state and an oxidized quinine conformation. Quinones have been well studied as redox mediators, transfering electrons from bacteria to ferric compounds,39 heavy metals40,41 and nitroaromatic compounds,42 etc. Particularly, B. subtilis contains a transmembrane succinate:menaquinone oxidoreductase (SQR) which can transfer electrons from intracellular succinate to extracellular menaquinone.43
In order to further explore the mechanism of the bacterial reduction of GO by VK3 mediated B. subtilis, a SQR inhibition assay was performed. It is reported that 2-n-heptyl-4-hydroxyquinoline-N-oxide (HQNO) is a menaquinone antagonist, which is a well-known inhibitor of B. subtilis SQR. It reacts with SQR and prevents the menaquinone binding. But the binding affinity of HQNO is not as strong as menaquinone.44 The corrected OD600 absorbance values of the BRGO reaction mixing (GO, B. subtilis 168 and VK3) with various concentrations of HQNO over time were monitored to quantitatively analyze the effect of HQNO on the biological reduction of GO. As shown in Fig. 2b, due to the lower affinity to SQR than VK3, when only 10 μmol L−1 of HQNO was present in the system, the bacterial reduction of GO suppressed only a little. As HQNO concentration increased to 100 μmol L−1, the VK3 mediated bacterial reduction of GO was suppressed approximately 20%. This result is a strong proof of the biological GO reduction mechanism in which VK3 might mediate the electron transfer between the SQR of B. subtilis 168 and GO.
Therefore, a mechanism by which VK3 facilitates the reduction of GO was proposed as follows (Fig. 3). Through a third class of SQR, B. subtilis first transfers electrons from succinate (with a midpoint potential, Em, equal to +30 mV) to VK3 (Em = −75 mV).45 Then, the reducing form of VK3 transfers electrons to GO and forms BRGO. The oxidized VK3 goes back to the SQR to receive electrons again.
 |
| | Fig. 3 Electron transfer between B. subtilis 168 and GO mediated by VK3. | |
Raman spectral analysis
As one of the most powerful tools for analyzing carbon materials, Raman spectroscopy is always used to distinguish the character differences between GO and reduced GO, such as the number of layers,46,47 defects48 and so on. The Raman spectrum of graphene oxide (Fig. 4) displays two main features: the G-peak which is generally located at ∼1588 cm−1 accounts for the first order scattering of the E2g phonon from sp2 carbon atoms and the D-peak located at ∼1353 cm−1 accounts for the breathing mode of the κ-point phonon from A1g symmetry. After the reduction of the GO by B. subtilis 168 mediated with VK3, we observed an apparent red shift of the G-peak. The G-peak was broadened and shifted to 1581 cm−1. It is reported that the wavenumber of the G-peak correlates with the number of layers;46,47 the G peak of single layer GO is located at 1588 cm−1, while that of bacterially reduced GO is red shifted 7 cm−1, suggesting the formation of 2–6 layers of bacterially reduced GO. Moreover, the variation in relative intensity of the G-peak usually reveals changes in the electronic conjugation state, which suggests an alteration in the number of sp2 domains.49 In comparison to pure GO, the intensity ratio (ID/IG) improved from 0.92 to 1.01 after reduction by B. subtilis 168 and VK3, indicating the introduction of sp3 defects after functionalization. The 2D peaks of BRGO appear at around 2681 cm−1, exhibiting a broader and up-shifted peak in the Raman spectra, indicating the formation of multi-layer graphene sheets. The results of our Raman spectroscopy analysis are in good agreement with the previous studies,50 which indicated the positive reduction effect by B. subtilis 168 and VK3.
 |
| | Fig. 4 Raman spectra with low (a) and high (b) resolution of GO and BRGO. | |
SEM and TEM analysis
Both SEM and TEM microscopes are important tools for the observation of microscopic structure. The SEM images (Fig. 5a) and TEM images (Fig. 5c) reveal that GO has a wavy, folded shape and exists in the form of thin layers. As shown in Fig. 5b, SEM images reveal that the BRGO uniformly consists of several layers stacked on top of one another like sheets of paper. The TEM images (Fig. 5d) of the BRGO look like a transparent silk veil with crumpled or wrinkled structure, which indicates that the graphene formation consists of only a few layers.
 |
| | Fig. 5 SEM and TEM images of GO (a and c) and BRGO (b and d). | |
XPS analysis
XPS is a very sensitive qualitative analysis technique used to determine the kinetic energy and number of electrons emitted, yielding clues about the graphene's composition and electronic state. Therefore, XPS was performed to determine the surface elements of GO and BRGO. As shown in Fig. 6a, the C1s XPS spectra peaks for pristine GO centered at 284, 284.8, 286 and 287.2 eV, which were assigned to C–C/C
C, C–OH, C–O–C and HO–C
O, respectively.51 The peak intensity of the C–C/C
C bond was less prominent when compared with that of the C–O, C
O and O–C
O bonds in GO, demonstrating that the carbon sheets contained many oxygen-containing groups within the GO. As shown in Fig. 6b, in addition to the four peaks for GO, there were 5 peaks for the BRGO, and the positions of the peaks shifted slightly. The C1s of C–C/C
C, C–OH, C–O–C, C
O and HO–C
O were located at 284, 284.8, 285.8, 286.7 and 287.2 eV. The new peak was assigned to C
O, may be due to the reduction of C–O–C and HO–C
O. More importantly, after bacterial reduction, the strongest signal came from the C–C/C
C bond and the C–O bond had obviously decreased in intensity, the results confirmed that most of the oxygen containing functional groups were removed and the substantial sp2 carbon characteristics had been partially restored by the VK3 mediated B. subtilis 168 reduction of GO.
 |
| | Fig. 6 High-resolution XPS C1s spectra of (a) GO and (b) BRGO, and the survey XPS spectra of (c) BRGO and GO. | |
XRD analysis
As an effective method for investigating the interlayer changes and the crystalline properties of the synthesized material, XRD was carried out to characterize the GO and BRGO. Pristine exfoliated GO exhibits a diffraction peak at 2θ = 9.68° (Fig. 7), corresponding to an interlayer spacing (d-spacing) of 0.92 nm, which means that GO has a large interlayer distance due to the interposition of oxygen-containing functional groups, such as hydroxyl, epoxy, and carboxyl groups, during the oxidation process.52 After GO reduction by B. subtilis 168 together with VK3, the XRD pattern appeared as a broad peak, centered around at 2θ = 24.18°, with a decreasing interlayer spacing of 0.37 nm, indicating the removal of oxygen-containing groups and the formation of a fewer layered graphene.53
 |
| | Fig. 7 XRD patterns on BRGO and GO. | |
Hatching rate, viability, heart rate and body length assessment
The zebrafish has high homology with the human genome and thus has been used extensively in the study of vertebrate genetics, developmental biology54 and drug screening.55 Recently, the zebrafish gained acceptance as an animal model for “predictive toxicology” at the Food and Drug Administration's (FDA) National Center for Toxicological Research (NCTR) (http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm343940.htm). European legislation also considers the zebrafish embryo an alternative to animal experiments and consistent with the 3R approach that is, reduction, refinement and replacement of the mammalian models for toxicity screening.56 The zebrafish model has been extensively used for toxicity screens over a wide array of nanomaterials, including metal nanoparticles, carbon-based nanomaterials and polymers.57 Therefore, hatching rate, viability, heart rate and body length assessment were used to evaluate the toxicity and biocompatibility of GO, CRGO and BRGO in vivo, via the zebrafish model.
Hatching is considered an important event within the course of embryogenesis and thus is a key endpoint for the embryo toxicity test. The hatching rates of the zebrafish embryos exposed to the GO, CRGO and BRGO are shown in Fig. 8a. Compared with the BRGO-treated group, the CRGO and GO-treated groups showed a significant dose-dependent decrease in hatching rate. The hatching rates for embryos treated with CRGO and GO were 93%, 73%, 53%, 43% and 83%, 80%, 70%, 53% at 20, 50, 100, 200 mg L−1, respectively. On the other hand, BRGO had no effect on the hatching. We also observed that all three nanomaterials did not cause any malformation during embryogenesis. Most of the embryos that failed to hatch were dead after exposure to the nanomaterials. Subsequently, a similar dose–response pattern was found in the viability assay (Fig. 8b).
 |
| | Fig. 8 Toxicity assessment of three graphene materials. (a) Hatching rate, (b) viability, (c) heart rate and (d) body length of zebrafish embryos exposed to GO, CRGO, and BRGO, at concentrations ranging from 20 to 200 mg L−1. Each point represents a mean ± standard error of the mean (SEM) from a representative experiment. * P < 0.05, ** P < 0.01, and *** P < 0.001 in one-way ANOVA analysis followed by the Dunnett multiple comparision test. | |
Heart rate is an important indicator for cardiovascular toxicity. The heart rates of the zebrafish embryos were recorded at 72 hpf after exposure to the 3 nanomaterials at different concentrations. The results are shown in Fig. 8c. The heart rate of the embryos exposed to GO and CRGO at 72 hpf was decreased over the test range from 20–200 mg L−1, though the significance was only obvious within the 200 mg L−1 CRGO treatment group. The BRGO had no effect on the heart rate at any of the tested concentrations.
Similar results were observed in the body length assessment (Fig. 8d). The body length of embryos exposed to GO and CRGO at 72 hpf was decreased from 20–200 mg L−1, but significance was only obvious within the 200 mg L−1 CRGO treatment group. Again, BRGO had no effect on the body length at any of the tested concentrations.
The hatching of the embryos seemed to display the most sensitivity to graphene material exposure among all these toxicity tests. As shown in the image of zebrafish embryos exposed to different concentrations of GO, CRGO and BRGO (Fig. 9), the differences in the effect of these three graphene materials on hatching rate (Table 1) might be due to CRGO and GO impairing the enzyme digestion of the chorion by the embryos or the CRGO and the GO may have aggregated and adhered to the surface of the chorion of the embryos.57
 |
| | Fig. 9 Effect of exposure to different concentrations (0, 20, 50, 100, 200 mg L−1) of (a) GO, (b) CRGO, (C) BRGO on the surface of the chorion of zebrafish embryos. Photos were taken at 24 hpf. | |
Table 1 Hatching rate (%) of zebrafish embryos treated by GO, CRGO, and BRGO at different concentrations
| Concentration (mg L−1) |
0 |
20 |
50 |
100 |
200 |
| GO |
83 |
83 |
80 |
70 |
53 |
| CRGO |
93 |
93 |
73 |
53 |
43 |
| BRGO |
96 |
93 |
76 |
86 |
83 |
Different from previously reported bacteria, our reducing agent B. subtilis is a “GRAS” microorganism which does not produce toxins and other pernicious proteins.58 Therefore, the synthesis of BRGO by VK3 mediated B. subtilis is a safer, as well as a more reliable, cost-effective and eco-friendly process. According to our zebrafish toxicity assessments, BRGO showed more biocompatibility and less toxicity than either GO or CRGO, which illuminates its potential in biomedical application.
Conclusions
Here we have provided a demonstration of an eco-friendly approach to the reduction of GO using a “GRAS” strain of B. subtilis 168 mediated by VK3, which opens up the possibility of a green synthesis of graphene. The mechanism of reduction that is proposed is that GO might be reduced by the VK3 mediated electron transfer via the SQR of B. subtilis 168. The bacterial reduction of GO has been confirmed by Raman spectroscopy, XPS and XRD. Moreover, the in vivo toxicity assessment, including hatching rate, viability, heart rate and body length using the zebrafish model, illustrated that BRGO has a lower toxicity and higher biocompatibility when compared to GO and CRGO. This work broadens our knowledge of the synthesis of graphene by bacteria, while providing a safe and biocompatible reductant for the green synthesis of nanomaterials.
Acknowledgements
This study was supported by the National Basic Research Program of China (973) (Grant No. 2012CB721100, 2011CBA00806); the National Science Fund of China (Grant No. 21306083, 21390201); the Fund from the State Key Laboratory of Materials-Oriented Chemical Engineering (ZK201312); Technology supporting program of Jiangsu Province (Grant No. BE2014901) and the Priority Academic Program from Development of Jiangsu Higher Education Institutions.
Reference
- A. K. Geim and K. S. Novoselov, Nat. Mater., 2007, 6, 183–191 CrossRef CAS PubMed.
- S. Stankovich, D. A. Dikin, G. H. Dommett, K. M. Kohlhaas, E. J. Zimney, E. A. Stach, R. D. Piner, S. T. Nguyen and R. S. Ruoff, Nature, 2006, 442, 282–286 CrossRef CAS PubMed.
- K. S. Novoselov, A. K. Geim, S. V. Morozov, D. Jiang, Y. Zhang, S. V. Dubonos, I. V. Grigorieva and A. A. Firsov, Science, 2004, 306, 666–669 CrossRef CAS PubMed.
- S. Chen, Q. Wu, C. Mishra, J. Kang, H. Zhang, K. Cho, W. Cai, A. A. Balandin and R. S. Ruoff, Nat. Mater., 2012, 11, 203–207 CrossRef CAS PubMed.
- C. Lee, X. Wei, J. W. Kysar and J. Hone, Science, 2008, 321, 385–388 CrossRef CAS PubMed.
- A. T. Lawal, Talanta, 2015, 131, 424–443 CrossRef CAS PubMed.
- S. Goenka, V. Sant and S. Sant, J. Controlled Release, 2013, 173, 75–88 CrossRef PubMed.
- Y. Zhu, S. Murali, W. Cai, X. Li, J. W. Suk, J. R. Potts and R. S. Ruoff, Adv. Mater., 2010, 22, 3906–3924 CrossRef CAS PubMed.
- M. D. Stoller, S. J. Park, Y. W. Zhu, J. H. An and R. S. Ruoff, Nano Lett., 2008, 8, 3498–3502 CrossRef CAS PubMed.
- S. Z. Zhu and T. Li, ACS Nano, 2014, 8, 2864–2872 CrossRef CAS PubMed.
- G. Lalwani, A. M. Henslee, B. Farshid, L. Lin, F. K. Kasper, Y. X. Qin, A. G. Mikos and B. Sitharaman, Biomacromolecules, 2013, 14, 900–909 CrossRef CAS PubMed.
- S. Kanakia, J. D. Toussaint, S. M. Chowdhury, G. Lalwani, T. Tembulkar, T. Button, K. R. Shroyer, W. Moore and B. Sitharaman, Int. J. Nanomed., 2013, 8, 2821–2833 Search PubMed.
- G. Lalwani, X. Cai, L. Nie, L. V. Wang and B. Sitharaman, Photoacoustics, 2013, 1, 62–67 CrossRef PubMed.
- Z. Liu, J. T. Robinson, X. Sun and H. Dai, J. Am. Chem. Soc., 2008, 130, 10876–10877 CrossRef CAS PubMed.
- R. Tkacz, R. Oldenbourg, S. B. Mehta, M. Miansari, A. Verma and M. Majumder, Chem. Commun., 2014, 50, 6668–6671 RSC.
- R. S. Dey and C. R. Raj, J. Phys. Chem. C, 2010, 114, 21427–21433 CAS.
- M. A. Eckert, P. Q. Vu, K. Zhang, D. Kang, M. M. Ali, C. Xu and W. Zhao, Theranostics, 2013, 3, 583–594 CrossRef PubMed.
- K. Rajavel, C. R. Minitha, K. S. Ranjith and R. T. Rajendra Kumar, Recent Pat. Nanotechnol., 2012, 6, 99–104 CrossRef CAS.
- L. L. Abell, B. B. Levy, B. B. Brodie and F. E. Kendall, J. Biol. Chem., 1952, 195, 357–366 CAS.
- G. B. Rybicki and D. G. Hummer, Astron. Astrophys., 1991, 245, 171–181 CAS.
- H. J. Shin, K. K. Kim, A. Benayad, S. M. Yoon, H. K. Park, I. S. Jung, M. H. Jin, H. K. Jeong, J. M. Kim, J. Y. Choi and Y. H. Lee, Adv. Funct. Mater., 2009, 19, 1987–1992 CrossRef CAS PubMed.
- United States Environmental Protection Agency, Hydrazine Hazard Summary, 2000, http://www.epa.gov/airtoxics/hlthef/hydrazin.html.
- Z. Zhang, H. H. Chen, C. Y. Xing, M. Y. Guo, F. G. Xu, X. D. Wang, H. Gruber, B. L. Zhang and J. L. Tang, Nano Res., 2011, 4, 599–611 CrossRef CAS.
- M. J. Fernandez-Merino, L. Guardia, J. I. Paredes, S. Villar-Rodil, P. Solis-Fernandez, A. Martinez-Alonso and J. M. D. Tascon, J. Phys. Chem. C, 2010, 114, 6426–6432 CAS.
- C. Z. Zhu, S. J. Guo, Y. X. Fang and S. J. Dong, ACS Nano, 2010, 4, 2429–2437 CrossRef CAS PubMed.
- E. C. Salas, Z. Z. Sun, A. Luttge and J. M. Tour, ACS Nano, 2010, 4, 4852–4856 CrossRef CAS PubMed.
- S. Gurunathan, J. W. Han, V. Eppakayala, M. Jeyaraj and J. H. Kim, J. Nanosci. Nanotechnol., 2013, 13, 2091–2098 CrossRef CAS PubMed.
- S. Raveendran, N. Chauhan, Y. Nakajima, H. Toshiaki, S. Kurosu, Y. Tanizawa, R. Tero, Y. Yoshida, T. Hanajiri and T. Maekawa, Part. Part. Syst. Charact., 2013, 30, 573–578 CrossRef CAS PubMed.
- S. Gurunathan, J. W. Han, V. Eppakayala and J.-H. Kim, Colloids Surf., B, 2013, 105, 58–66 CrossRef CAS PubMed.
- A. G. Nandgaonkar, Q. Wang, K. Fu, W. E. Krause, Q. Wei, R. Gorga and L. A. Lucia, Green Chem., 2014, 16, 3195 RSC.
- S. Gurunathan, J. W. Han, V. Eppakayala and J.-H. Kim, Int. J. Nanomed., 2013, 8, 1015 CrossRef PubMed.
- G. Liu, X. Zhang, J. Zhou, A. Wang, J. Wang, R. Jin and H. Lv, Bioresour. Technol., 2013, 149, 503–508 CrossRef CAS PubMed.
- P. Guo, F. Xiao, Q. Liu, H. Liu, Y. Guo, J. R. Gong, S. Wang and Y. Liu, Sci. Rep., 2013, 3, 3499 Search PubMed.
- M. Fan, C. Zhu, Z. Q. Feng, J. Yang, L. Liu and D. Sun, Nanoscale, 2014, 6, 4882–4888 RSC.
- Y. Yuan, F. Feng, L. Chen and K. Chen, Eur. Food Res. Technol., 2013, 238, 285–293 CrossRef.
- M. F. He, X. P. Gao, S. C. Li, Z. H. He, N. Chen, Y. B. Wang and J. X. She, Eur. J. Pharmacol., 2014, 740, 240–247 CrossRef CAS PubMed.
- M. Westerfield, The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish, The University of Oregon Press, Eugene, OR, 2007 Search PubMed.
- G. M. Wang, F. Qian, C. Saltikov, Y. Q. Jiao and Y. Li, Nano Res., 2011, 4, 563–570 CrossRef CAS PubMed.
- T. Borch, W. P. Inskeep, J. A. Harwood and R. Gerlach, Environ. Sci. Technol., 2005, 39, 7126–7133 CrossRef CAS.
- S. Yamamura, M. Watanabe, M. Kanzaki, S. Soda and M. Ike, Environ. Sci. Technol., 2008, 42, 6154–6159 CrossRef CAS.
- B. H. Jeon, S. D. Kelly, K. M. Kemner, M. O. Barnett, W. D. Burgos, B. A. Dempsey and E. E. Roden, Environ. Sci. Technol., 2004, 38, 5649–5655 CrossRef CAS.
- R. P. Schwarzenbach, R. Stierli, K. Lanz and J. Zeyer, Environ. Sci. Technol., 1990, 24, 1566–1574 CrossRef CAS.
- L. Hederstedt, Biochim. Biophys. Acta, 2002, 1553, 74–83 CrossRef CAS.
- I. A. Smirnova, A. A. Konstantinov and L. Hederstedt, FEBS Lett., 1994, 359, 23–26 CrossRef.
- C. Hagerhall, Biochim. Biophys. Acta, 1997, 1320, 107–141 CrossRef CAS.
- D. C. Wei, Y. Q. Liu, Y. Wang, H. L. Zhang, L. P. Huang and G. Yu, Nano Lett., 2009, 9, 1752–1758 CrossRef CAS PubMed.
- D. Graf, F. Molitor, K. Ensslin, C. Stampfer, A. Jungen, C. Hierold and L. Wirtz, Nano Lett., 2007, 7, 238–242 CrossRef CAS PubMed.
- A. Das, B. Chakraborty and A. K. Sood, Bull. Mater. Sci., 2008, 31, 579–584 CrossRef CAS PubMed.
- S. Niyogi, E. Bekyarova, M. E. Itkis, H. Zhang, K. Shepperd, J. Hicks, M. Sprinkle, C. Berger, C. N. Lau, W. A. deHeer, E. H. Conrad and R. C. Haddon, Nano Lett., 2010, 10, 4061–4066 CrossRef CAS PubMed.
- S. Gurunathan, J. W. Han, V. Eppakayala and J. H. Kim, Colloids Surf., B, 2013, 105, 58–66 CrossRef CAS PubMed.
- S. Stankovich, D. A. Dikin, R. D. Piner, K. A. Kohlhaas, A. Kleinhammes, Y. Jia, Y. Wu, S. T. Nguyen and R. S. Ruoff, Carbon, 2007, 45, 1558–1565 CrossRef CAS PubMed.
- D. R. Dreyer, S. Park, C. W. Bielawski and R. S. Ruoff, Chem. Soc. Rev., 2010, 39, 228–240 RSC.
- I. K. Moon, J. Lee, R. S. Ruoff and H. Lee, Nat. Commun., 2010, 1, 73, DOI:10.1038/ncomms1067.
- A. F. Schier, Nature, 2013, 496, 443–444 CrossRef CAS PubMed.
- A. J. Rennekamp and R. T. Peterson, Curr. Opin. Chem. Biol., 2014, 24C, 58–70 Search PubMed.
- H. Sukardi, H. T. Chng, E. C. Chan, Z. Gong and S. H. Lam, Expert Opin. Drug Metab. Toxicol., 2011, 7, 579–589 CrossRef CAS PubMed.
- V. E. Fako and D. Y. Furgeson, Adv. Drug Delivery Rev., 2009, 61, 478–486 CrossRef CAS PubMed.
- A. S. de Boer and B. Diderichsen, Appl. Microbiol. Biotechnol., 1991, 36, 1–4 CrossRef CAS.
Footnote |
| † Present Address: College of Biotechnology and pharmaceutical Engineering, Nanjing Tech University, 30 South Puzhu Road, Nanjing 211816, P. R. China, Tel. +86 25 58139939. |
|
| This journal is © The Royal Society of Chemistry 2015 |
Click here to see how this site uses Cookies. View our privacy policy here.